Surmodics, Inc. (SRDX)

Market Cap	569.46M
Revenue (ttm)	126.08M
Net Income (ttm)	-11.54M
Shares Out	14.33M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,842
Open	40.10
Previous Close	39.91
Day's Range	39.60 - 40.10
52-Week Range	25.17 - 42.44
Beta	1.22
Analysts	Hold
Price Target	43.00 (+8.18%)
Earnings Date	Jan 30, 2025

About SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 4, 1998
• Employees: 389
• Stock Exchange: NASDAQ
• Ticker Symbol: SRDX
• Website: https://www.surmodics.com

Financial Performance

In 2024, Surmodics's revenue was $126.08 million, a decrease of -4.91% compared to the previous year's $132.58 million. Losses were -$11.54 million, 651.4% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for SRDX stock is "Hold." The 12-month stock price forecast is $43.0, which is an increase of 8.18% from the latest price.

Price Target

$43.0

(8.18% upside)

Analyst Consensus: Hold